Branch Atheromatous Disease (BAD)-type Cerebral Infarction
Conditions
Interventions
FFor patients with Branch Atheromatous Disease, clopidogrel is administered with a loading dose of 300 mg orally (75 mg x 4), followed by a maintenance dose of 75 mg/day. Aspirin is co-administered at
Sponsors
Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are eligible for inclusion: 1. Acute cerebral infarction diagnosed as Branch Atheromatous Disease (BAD) within 24 hours of onset 2. Age >= 20 years 3. Written informed consent obtained from the patient or a legally authorized representative
Exclusion criteria
Exclusion criteria: Patients will be excluded if they meet any of the following criteria: Received acute reperfusion therapy (intravenous tPA or endovascular treatment) Severe stenosis (>50%) or occlusion of the responsible artery Strong suspicion of cardiogenic cerebral embolism (e.g., atrial fibrillation) Active bleeding or bleeding tendency Receiving anticoagulant therapy other than antiplatelet agents History of allergy to prasugrel or clopidogrel Ineligible for MRI (e.g., pacemaker, metallic implant, severe claustrophobia) Deemed inappropriate for participation by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early neurological deterioration (END) occurring within 48 hours and within 7 days after the initiation of treatment. END is defined as a worsening of the total NIHSS (National Institutes of Health Stroke Scale) score by 2 points or more. | — |
Countries
Japan
Contacts
Public ContactNoriko Arai
Saitama Medical University International Medical Center Department of Neurology and Cerebrovascular Medicine
Outcome results
None listed